Progress is a concept that's pretty much always both subjective and relative -- after all, more than one company has pointed toward doing less badly as "progress." And so it would seem to be with Tenet Healthcare
In the quarter that was, total operating revenue rose 2.5% as admissions were down (2.7% for inpatient, 1.9% on an equivalent basis), but pricing was stronger. While the company did report a loss from continuing operations, adjusted EBITDA rose 37% and the margin rose to 9.5%. Even if you exclude some items, margins improved, but there's still a sizable gulf between today's level and the 11%-13% target range.
What's more, there are some definite ongoing pressures on the company. Like Lifepoint
I have to admit a soft spot for this kind of risky turnaround, partly because I've had a lot of success with them in the past. In the case of Tenet, the company needs to see volume growth and better bad debt results, and it saw neither this quarter (on a year-over-year basis). That's a tough hurdle, particularly when everybody else in the industry has the same basic goals in mind. Moreover, I really don't expect much outside help -- Congress doesn't seem willing or able to tackle the situation in a way that would really change anything.
If things go right, this is at least a double. If things go wrong, bankruptcy is not out of the question. That's a pretty stark contrast, but that's the way it works with these stocks. Fools who want to dabble here should be extra careful on their due diligence; it's a long slog ahead, so make sure you really know what you're getting yourself into with Tenet Healthcare.
For more medical missives:
Tenet Healthcare is a recommendation of Motley Fool Stock Advisor , where Tom and David Gardner are always on the lookout for the market's best investments. Try it out for yourself -- it's free for 30 days .
Fool contributor Stephen Simpson has no financial interest in any stocks mentioned (that means he's neither long nor short the shares).